PCSK1

(redirected from SPC3)

PCSK1

A gene on chromosome 5q15-q21 that encodes a peptidase S8 family convertase involved in processing pairs of basic amino acid residues located on prohormones and other protein precursors (e.g., POMC, renin, enkephalin, dynorphin, somatostatin and insulin).

Molecular pathology
Defects in PCSK1 cause proprotein convertase 1 deficiency.
References in periodicals archive ?
In laboratory tests, SPC3 blocks the spread of infection by many different strains of HIV, including those resistant to AZT.
We are encouraged by the recent developments in HIV co-receptor research, but must caution everyone that SPC3 is still in a very early stage of development," said William J.
clinical trials for their AIDS therapy drug, SPC3 (Synthetic Polymeric Construction No.
The primary objective of the clinical trials (Phase I/II studies) which begin this fall, is to determine the optimal dosage of SPC3 in late stage seropositive patients.
SPC3 protects the human cells including CD4+ lymphocytes, macrophages and CD4- negative cells by obstructing entry of the HIV virus.
In-vitro studies have demonstrated that SPC3 effectively blocks entrance of all strains of the virus into human cells, unlike previously tested antiviral agents and vaccines that are strain specific.
ASE:COB) Thursday announced that it commenced Phase II/III clinical trials in the United Kingdom for SPC3, a potential AIDS treatment.
The objective of the studies is to demonstrate that SPC3 inhibits production of the AIDS virus and prevents progression to full blown AIDS in patients with late stage HIV infection.
We are excited with the progress on the development of SPC3,'' said William J.
A synthetic multi-branched peptide, SPC3 contains eight repeats of the consensus region of the V3 loop of the HIV-1 (AIDS) virus surface envelope glycoprotein gp120.
The relative specificity of the SPC3 peptide for its receptor ensures that it is free of the significant side effects associated with the reverse transcriptuse and protease inhibitors used in current treatments.
Preliminary studies demonstrated that SPC3 acts at least in part by blocking the fusion process.